A Phase 2 interventional study of Antidepressant + SPD489 (lisdexamfetamine dimesylate) and Antidepressant + placebo in Major Depressive Disorder, sponsored by Shire. Completed at 15 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2009, is one of 4 in phase 2, and was the 5th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 17 · Phase 4 3
First in 2008; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 580 across the 24 interventional studies, 73,904 across the 2 observational. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Depressive Disorder, Major by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Antidepressant + SPD489
Drug: Antidepressant + SPD489 (lisdexamfetamine dimesylate)
Antidepressant + placebo
Drug: Antidepressant + placebo
Drug page: Lisdexamfetamine
Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
Also known as: LDX, Vyvanse
Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF)
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Augmentation Baseline, 6 weeks
Change From Augmentation Baseline for Non-Remitters in the Hamilton Depression Scale (HAM-D) Total Score at Week 6 - LOCF
The HAM-D is a validated rating scale which consists of 17 items. Nine of the items are scored on a scale of 0-4 and 8 items are scored on a scale of 0-2 for a total scoring range of 0-52. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates increased severity of depression. In general, the lower the total score the less severe the depression.
Time frame: Augmentation Baseline, 6 weeks
Change From Augmentation Baseline for Non-Remitters in the Sheehan Disability Scale (SDS) Total Score at Week 6
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
Time frame: Augmentation Baseline, 6 weeks
Percentage of Non-Remitters With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 6 - LOCF
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: 6 weeks
Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Augmentation baseline
Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Week 6
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: 6 weeks
Change From Augmentation Baseline for Non-Remitters in the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Scale Total Score at Week 6
BRIEF-A is a validated 75-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to develop interpretive reports. Lower scores reflect better functioning.
Time frame: Augmentation Baseline and 6 weeks
Change From Augmentation Baseline for Non-Remitters in the Multidimensional Assessment of Fatigue (MAF) Scale Total Score at Week 6
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.
Time frame: Augmentation Baseline and 6 weeks
Change From Augmentation Baseline for Non-Remitters in the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) Scale Total Score at Week 6
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression.
Time frame: Augmentation Baseline and 6 weeks
Change From Augmentation Baseline for Remitters in MADRS Total Score at Week 6 - LOCF
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Augmentation Baseline and 6 weeks
Change From Augmentation Baseline for Remitters in the HAM-D Total Score at Week 6 - LOCF
The HAM-D is a validated rating scale which consists of 17 items. Nine of the items are scored on a scale of 0-4 and 8 items are scored on a scale of 0-2 for a total scoring range of 0-52. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates increased severity of depression. In general, the lower the total score the less severe the depression.
Time frame: Augmentation Baseline and 6 weeks
Change From Augmentation Baseline for Remitters in the SDS Total Score at Week 6
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
Time frame: Augmentation Baseline and 6 weeks
Percentage of Remitters With Improvement on CGI-I at Week 6 - LOCF
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: 6 weeks
Assessment in Remitters of CGI-S at Augmentation Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Augmentation Baseline
Assessment in Remitters of CGI-S at Week 6
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: 6 weeks
Change From Augmentation Baseline for Remitters in the BRIEF-A Scale Total Score at Week 6
BRIEF-A is a validated 86-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Lower scores reflect better functioning.
Time frame: Augmentation baseline and 6 weeks
Change From Augmentation Baseline for Remitters in the MAF Scale Total Score at Week 6
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.
Time frame: Augmentation baseline and 6 weeks
Change From Augmentation Baseline for Remitters in the QIDS-SR Scale Total Score at Week 6
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression.
Time frame: Augmentation baseline and 6 weeks
| Milestone | Antidepressant + SPD489 | Antidepressant + Placebo . |
|---|---|---|
| Started | 89 | 88 |
| Completed | 78 | 79 |
| Not completed | 11 | 9 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Non-compliance with study medication | 2 | 0 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Positive urine drug screen | 0 | 1 |
| Withdrew: Non-adherence to visit schedule | 0 | 1 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| Units on a scale | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF) | -7.1 ± 0.93 | -4.9 ± 0.94 |
The HAM-D is a validated rating scale which consists of 17 items. Nine of the items are scored on a scale of 0-4 and 8 items are scored on a scale of 0-2 for a total scoring range of 0-52. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates increased severity of depression. In general, the lower the total score the less severe the depression.
| Units on a scale | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Change From Augmentation Baseline for Non-Remitters in the Hamilton Depression Scale (HAM-D) Total Score at Week 6 - LOCF | -4.9 ± 0.64 | -4.0 ± 0.65 |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
| Units on a scale | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Change From Augmentation Baseline for Non-Remitters in the Sheehan Disability Scale (SDS) Total Score at Week 6 | -3.7 ± 0.73 | -1.7 ± 0.74 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percent of Participants | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Percentage of Non-Remitters With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 6 - LOCF | 60.0 | 45.3 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Normal, not at all ill | 1.5 | 1.6 |
| Borderline mentally ill | 20.0 | 12.5 |
| Mildly ill | 40.0 | 34.4 |
| Moderately ill | 32.3 | 48.4 |
| Markedly ill | 6.2 | 3.1 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Normal, not at all ill | 27.0 | 14.5 |
| Borderline mentally ill | 31.7 | 24.2 |
| Mildly ill | 30.2 | 22.6 |
| Moderately ill | 9.5 | 29.0 |
| Markedly ill | 1.6 | 9.7 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
BRIEF-A is a validated 75-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to develop interpretive reports. Lower scores reflect better functioning.
| Units on a scale | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Global Executive Composite | -4.7 ± 1.03 | -1.7 ± 1.04 |
| Behavioral Regulation Index | -3.7 ± 0.97 | -1.7 ± 0.99 |
| Metacognition Index | -4.8 ± 1.04 | -1.5 ± 1.06 |
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.
| Units on a scale | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Change From Augmentation Baseline for Non-Remitters in the Multidimensional Assessment of Fatigue (MAF) Scale Total Score at Week 6 | -5.3 ± 1.25 | -2.3 ± 1.26 |
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression.
| Units on a scale | Antidepressant + SPD489 (Non-remitters) | Antidepressant + Placebo (Non-remitters) |
|---|---|---|
| Change From Augmentation Baseline for Non-Remitters in the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) Scale Total Score at Week 6 | -2.4 ± 0.45 | -1.2 ± 0.46 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| Units on a scale | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Change From Augmentation Baseline for Remitters in MADRS Total Score at Week 6 - LOCF | 0.1 ± 1.13 | -1.1 ± 1.18 |
The HAM-D is a validated rating scale which consists of 17 items. Nine of the items are scored on a scale of 0-4 and 8 items are scored on a scale of 0-2 for a total scoring range of 0-52. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates increased severity of depression. In general, the lower the total score the less severe the depression.
| Units on a scale | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Change From Augmentation Baseline for Remitters in the HAM-D Total Score at Week 6 - LOCF | -0.8 ± 0.92 | -1.6 ± 0.96 |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
| Units on a scale | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Change From Augmentation Baseline for Remitters in the SDS Total Score at Week 6 | -1.6 ± 0.89 | -0.6 ± 0.91 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percent of participants | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Percentage of Remitters With Improvement on CGI-I at Week 6 - LOCF | 65.2 | 52.4 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Normal, not at all ill | 26.1 | 23.8 |
| Borderline mentally ill | 47.8 | 71.4 |
| Mildly ill | 21.7 | 4.8 |
| Moderately ill | 4.3 | 0 |
| Markedly ill | 0 | 0 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Normal, not at all ill | 50.0 | 61.9 |
| Borderline mentally ill | 36.4 | 23.8 |
| Mildly ill | 13.6 | 9.5 |
| Moderately ill | 0 | 4.8 |
| Markedly ill | 0 | 0 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
BRIEF-A is a validated 86-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Lower scores reflect better functioning.
| Units on a scale | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Global Executive Composite | -0.9 ± 1.21 | -2.7 ± 1.21 |
| Behavioral Regulation Index | -0.4 ± 1.37 | -1.5 ± 1.37 |
| Metacognition Index | -1.1 ± 1.24 | -3.4 ± 1.24 |
MAF contains 16 items scored on a scale from 1 (not at all) to 10 (a great deal). Answers are converted to a Global Fatigue Index with total scores ranging from 1 (no fatigue) to 50 (severe fatigue). Lower scores indicate less fatigue.
| Units on a scale | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Change From Augmentation Baseline for Remitters in the MAF Scale Total Score at Week 6 | -4.0 ± 1.77 | -0.2 ± 1.81 |
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression.
| Units on a scale | Antidepressant + SPD489 (Remitters) | Antidepressant + Placebo (Remitters) |
|---|---|---|
| Change From Augmentation Baseline for Remitters in the QIDS-SR Scale Total Score at Week 6 | -1.9 ± 0.57 | -0.4 ± 0.58 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Antidepressant + SPD489 | — | 0/88 (0%) | 35/88 (39.8%) |
| Antidepressant + Placebo . | — | 1/85 (1.2%) | 15/85 (17.6%) |
| Event | Antidepressant + SPD489 | Antidepressant + Placebo . |
|---|---|---|
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/88 | 1/85 |
| Event | Antidepressant + SPD489 | Antidepressant + Placebo . |
|---|---|---|
| Dry mouthGastrointestinal disorders | 10/88 | 0/85 |
| HeadacheNervous system disorders | 10/88 | 4/85 |
| InsomniaPsychiatric disorders | 4/88 | 6/85 |
| Decreased appetiteMetabolism and nutrition disorders | 6/88 | 2/85 |
| NasopharyngitisInfections and infestations | 5/88 | 3/85 |
| Age, Continuous(years) | Antidepressant + SPD489 | Antidepressant + Placebo . | Total |
|---|---|---|---|
| Mean | 39.4 ± 9.65 | 38.6 ± 10.38 | 39.0 ± 9.99 |
| Age, Customized(Participants) | Antidepressant + SPD489 | Antidepressant + Placebo . | Total |
|---|---|---|---|
| 18-40 years | 44 | 49 | 93 |
| 41-55 years | 44 | 36 | 80 |
| Sex: Female, Male(Participants) | Antidepressant + SPD489 | Antidepressant + Placebo . | Total |
|---|---|---|---|
| Female | 53 | 54 | 107 |
| Male | 35 | 31 | 66 |
| Region of Enrollment(Participants) | Antidepressant + SPD489 | Antidepressant + Placebo . | Total |
|---|---|---|---|
| United States | 88 | 85 | 173 |
Ran from Jul 2009 to primary completion in Aug 2010, 12 months.
Results were first posted in Jul 2011, 11 months after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 12 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine